Valuation: Pacific Software, Inc.

Market Cap 48.82M 43.8M 40.5M 36.68M 68.52M 4.65B 69.35M 484M 193M 2.43B 183M 179M 7.72B P/E 2019
-2.65x
P/E 2020 -41.2x
Enterprise Value 49.19M 44.13M 40.8M 36.95M 69.04M 4.68B 69.87M 488M 194M 2.45B 185M 181M 7.78B EV / Sales 2019
-
EV / Sales 2020 2,435,972,350x
Free-Float
64%
Yield 2019 *
-
Yield 2020 -
1 day-11.11%
Current month-18.37%
1 month-49.87%
3 months-2.44%
6 months-6.98%
Current year-66.67%
1 week 0.04
Extreme 0.04
0.06
1 month 0.04
Extreme 0.04
0.08
Current year 0.01
Extreme 0.0088
0.09
1 year 0.01
Extreme 0.0088
0.12
3 years 0
Extreme 0.001
0.3
5 years 0
Extreme 0.001
2.37
10 years 0
Extreme 0.001
5.59
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 10/06/2026
Director TitleAgeSince
Chairman 74 22/10/2016
Change 5-day change 1-year change 3-year change Capi.($)
-11.11%-.--%+669.23%-21.57% 4.06M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+2.76%+0.87%+27.92%+57.51% 44.75B
+2.00%-3.39%+17.83%+100.08% 41.62B
+1.34%-2.86%+224.43%+928.45% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +2.97%-0.38%+113.83%+144.61% 38.04B
Weighted average by Cap. +3.21%-0.29%+47.56%+161.71%

Financials

2019 2020
Net sales - 0.02 0.02 0.02 0.02 0.03 1.9 0.03 0.2 0.08 1 0.08 0.07 3.16
Net income -21.11M -18.94M -17.51M -15.86M -29.63M -2.01B -29.99M -209M -83.4M -1.05B -79.22M -77.55M -3.34B -1.17M -1.05M -974K -882K -1.65M -112M -1.67M -11.65M -4.64M -58.53M -4.41M -4.31M -186M
Net Debt -101K -90.22K -83.41K -75.54K -141K -9.58M -143K -997K -397K -5.01M -377K -369K -15.91M 367K 330K 305K 276K 516K 35M 522K 3.64M 1.45M 18.31M 1.38M 1.35M 58.14M
Logo Pacific Software, Inc.
PurMinds Enterprises, Inc., formerly Pacific Software, Inc., is a precision neuro-medicine development company pursuing solutions to neurological and psychiatric disorders. The Company's clinical pipeline includes neuroprotective compounds that restore neuronal functions and can address multiple clinical indications with significant unmet patient needs. The Company is focused on a 4P Medicine platform, in strategic partnership with SpectroChip Global Inc., for early detection and intervention of conditions before irreversible damage occurs. The Company operates under a Health Canada issued Controlled Drugs and Substances License. It has developed a pipeline of proprietary formulations and novel small molecules (NCEs). The Company's pipeline includes PUR100 Series and PUR500 Series.
Employees
2
Date Price Change Volume
27/10/26 $0.0650 +62.50% 139,999
26/10/26 $0.0400 -.--% 100,000
23/10/26 $0.0400 -18.37% 205,800
22/10/26 $0.0490 -2.00% 2,954
21/10/26 $0.0500 +25.00% 13,300
  1. Stock Market
  2. Stocks
  3. PFSF Stock